Publications by authors named "Jenna Bouassaly"
Article Synopsis
- * A review of 55 clinical trials showed that 83.3% were conducted after 2015, mainly in the U.S., focusing on various FDA-approved drugs for HNC, including cetuximab and pembrolizumab.
- * There is a need for new drugs specifically for HPV-associated OPC, as the molecular mechanisms and outcomes differ from HPV-negative cases; researchers have identified mutated genes in HPV-positive OPC that could be targeted for future drug development.
Head and neck cancer (HNC) is the 6th most common cancer across the world, with a particular increase in HNC associated with human papilloma virus (HPV) among younger populations. Historically, the standard treatment for this disease consisted of combined surgery and radiotherapy or curative platinum-based concurrent chemoradiotherapy, with associated long term and late toxicities. However, HPV-positive HNC is recognized as a unique cancer subtype, typically with improved clinical outcomes.
View Article and Find Full Text PDF